We are live on ! Find out more
SEEL

Seelos Therapeutics, Inc. Common Stock
SEEL

Delisted

SEEL was delisted on the 15th of October, 2024.

Back to rankings

2 hedge funds and large institutions have $4.2M invested in Seelos Therapeutics, Inc. Common Stock in 2017 Q1 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

64% more capital invested

Capital invested by funds: $2.56M → $4.2M (+$1.64M)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

33% less funds holding

Funds holding: 3 → 2 (-1)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

Holders
2
Holders Change
-1
Holders Change %
-33.33%
% of All Funds
0.05%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
–
Increased
1
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$553K

Top Sellers

Rank Fund Capital Flow
1
AFM
Anson Funds Management
Texas
-$263K
2
ARTA
A.R.T. Advisors
New York
-$19K
3
RJFSA
Raymond James Financial Services Advisors
Florida
-$14K
4
Creative Planning
Creative Planning
Kansas
-$1K
Name Holding Trade Value Shares
Change 		Change in
Stake
RJFSA
26
Raymond James Financial Services Advisors
Florida
– -$14K – –
1
2

SEEL Hedge Fund Activity: Q1 2017 in Review

2 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Seelos Therapeutics, Inc. Common Stock (SEEL) for Q1 2017, worth a combined $4.2M — up 64% from $2.56M a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of SEEL and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 1 added.

The largest buyer was Vanguard Group, adding an estimated $553K. The largest seller was Anson Funds Management, exiting entirely with an estimated $263K sold.

  • 2 institutional investors held Seelos Therapeutics, Inc. Common Stock (SEEL) as of Q1 2017, down from 3 in Q4 2016.
  • Funds reported $4.2M of Seelos Therapeutics, Inc. Common Stock stock for Q1 2017, up 64% quarter-over-quarter.
  • 0 funds opened new Seelos Therapeutics, Inc. Common Stock positions in Q1 2017 and 1 closed out, a net change of -1 holder.
  • The largest Seelos Therapeutics, Inc. Common Stock buyer in Q1 2017 was Vanguard Group, an estimated $553K added.
  • The largest Seelos Therapeutics, Inc. Common Stock seller in Q1 2017 was Anson Funds Management, an estimated $263K sold.

Based on aggregated 13F filings for Q1 2017.